Prognosis

OncoOne Announces Formation of Clinical Advisory Board to Support Development of ON104 for Chronic Inflammatory Diseases

Retrieved on: 
Tuesday, March 12, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Other Health, European Alliance, United, United Nations, Asthma, AAP, Yale school, CD74, Hôpital Cochin, Trinity College Dublin, Arthritis & Rheumatology, Molecular medicine, Cancer, University, Publication, Medical school, ASCI, Prognosis, Trinity, Pathology, Diagnosis, Public health, Trinity College, Arthritis, Physiology, Biomarker, Global Health, Nephritis, Society, EULAR, Inflammatory bowel disease, Physician, Pharmaceutical industry

OncoOne , a biotechnology company focused on discovering precision medicines for cancer and autoimmune diseases, announced today the formation of a clinical advisory board to provide strategic and clinical insights for the company’s lead program in immunology, ON104.

Key Points: 
  • OncoOne , a biotechnology company focused on discovering precision medicines for cancer and autoimmune diseases, announced today the formation of a clinical advisory board to provide strategic and clinical insights for the company’s lead program in immunology, ON104.
  • ON104 is a monoclonal antibody targeting the oxidized isoform of the macrophage migration inhibitory factor (oxMIF) for the treatment of chronic inflammatory diseases.
  • His research focuses on arthritis and other inflammatory rheumatic diseases, precision medicine, and the management of complex diseases.
  • Dr. Freissmuth is an inaugural member of OncoOne’s scientific advisory board, where he continues to support the development of the company’s pipeline of biotherapeutics.

UCLA and PreciseDx Announce New Collaboration to Advance AI-Enabled Predictions and Risk Mitigation for Triple-Negative Breast Cancer Recurrence

Retrieved on: 
Tuesday, April 2, 2024
HER2, Brain, Algorithm, Entrepreneurship, Immunotherapy, Disease, Risk, UCLA Health, Patient, Triple-negative breast cancer, Neoplasm, Research, MD, Medicine, Hospital, Breast cancer, Risk assessment, Pathology, Prognosis, Medical laboratory, Recurrence, TNBC, UCLA, Artificial intelligence, Health, Medical imaging

NEW YORK, April 2, 2024 /PRNewswire/ -- PreciseDx®, a leading innovator in oncology diagnostics leveraging Artificial Intelligence (AI) for revolutionary, morphology-driven disease analysis, today announced a sponsored research collaboration with UCLA's Department of Pathology and Laboratory Medicine in Los Angeles to evaluate PreciseBreast's™ ability to accurately assess risk of recurrence for patients with triple-negative breast cancer (TNBC). TNBC constitutes only 10-20% of all breast cancer cases, yet continues to demand significant clinical interest due to its limited response to conventional treatments, the association with younger women, BRCA1/2 mutations, ethnic/racial disparities, and its highly aggressive characteristics. 

Key Points: 
  • Our collaboration with PreciseDx has the potential to greatly improve our approach to predicting and managing recurrence in TNBC patients, ultimately leading to enhanced outcomes."
  • Integrating advanced AI algorithms and comprehensive clinical data, the collaborative study aims to confirm PreciseBreast as a highly effective and reliable digital breast cancer assay.
  • This new assay will potentially enhance the early detection of TNBC recurrence and support personalized treatment strategies tailored to individual patient needs.
  • The collaborative study between UCLA and PreciseDx represents a significant step forward in digital pathology and oncology breast cancer research.

Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status

Retrieved on: 
Tuesday, April 2, 2024
Toxicity, Radiation, Sintilimab, NMPA, Endometrial cancer, Disease, DCR, New Drug Application, Patient, Neoplasm, NDA, Cancer, Breakthrough therapy, Senior, HCM, HKEX, Dor, IRC, Prognosis, PFS, Ophthalmology, Pharmaceutical industry

The NDA is supported by data from FRUSICA-1, the endometrial cancer registration cohort of a multi-center, open-label Phase 2 study investigating sintilimab in combination with fruquintinib in endometrial cancer patients who experienced disease recurrence, disease progression or intolerable toxicity  with treatment on platinum-based doublet chemotherapy.

Key Points: 
  • The NDA is supported by data from FRUSICA-1, the endometrial cancer registration cohort of a multi-center, open-label Phase 2 study investigating sintilimab in combination with fruquintinib in endometrial cancer patients who experienced disease recurrence, disease progression or intolerable toxicity  with treatment on platinum-based doublet chemotherapy.
  • We are excited about the NDA acceptance and priority review designation, which increases our potential to bring a new treatment option to endometrial cancer patients, and concurrently strengthens the leadership position of TYVYT® in China."
  • We look forward to bringing this much-awaited treatment advancement to endometrial cancer patients to improve their treatment outcome."
  • The NMPA granted Breakthrough Therapy designation to the combination of sintilimab and fruquintinib for this potential indication in July 2023.

On Target Laboratories Founder Philip Low Receives Legacy Award from the American Lung Association

Retrieved on: 
Monday, April 1, 2024
Lung cancer, ALA, Organization, Innovation, Biotechnology, Disease, Cancer, Health, Patient, Legacy Award, Research, Laboratory, Surgeon, CVS Health, Prognosis, Purdue University

WEST LAFAYETTE, Ind., April 1, 2024 /PRNewswire/ -- Dr. Philip S. Low, Founder and Chief Science Officer of On Target Laboratories, Inc., will receive the Indiana American Lung Association's (ALA) Legacy Award for his lifetime and innovative work on targeted molecules. The annual Indiana ALA Legacy Award is given to individuals or organizations whose accomplishments are contributing to ending lung cancer and will be presented to Dr. Low at the ALA's "Evening of Promise Gala" in Indianapolis on Saturday, April 13. 

Key Points: 
  • Founder and Purdue University researcher Philip Low to be recognized for his invention of CYTALUX, a fluorescent targeted molecule that illuminates lung cancer cells during surgery
    WEST LAFAYETTE, Ind., April 1, 2024 /PRNewswire/ -- Dr. Philip S. Low, Founder and Chief Science Officer of On Target Laboratories, Inc., will receive the Indiana American Lung Association's (ALA) Legacy Award for his lifetime and innovative work on targeted molecules.
  • Dr. Low invented CYTALUX as part of his founding work with On Target Laboratories, a privately held biotechnology company whose mission is to illuminate cancer so it can be removed completely.
  • "We are proud that our Founder and Chief Science Officer, Dr. Low, is being celebrated for his dedication and innovative work to illuminate cancer during surgery," said Ben Lundgren, Chief Executive Officer of On Target Laboratories.
  • "I am honored to be receiving this year's Legacy Award from the Indiana American Lung Association," said Dr. Low.

DNA Methylation Detection Technology Markets, 2033 - Intensified Competition, Increasing Adoption, PCR Dominates

Retrieved on: 
Saturday, March 30, 2024
Diagnosis, PCR, Health, Growth, Biotechnology, Drug discovery, Thermo Fisher Scientific, Biomarker, Research, DNA, Competitive landscape, Real-time, Microarray, Cancer, Software, DNA methylation, Agilent Technologies, DSM-IV codes, QIAGEN, MSP, Prognosis, Marketing, Medicine, Fine chemical

In the DNA methylation detection technology market, several key players dominate the landscape with their diverse range of products and solutions.

Key Points: 
  • In the DNA methylation detection technology market, several key players dominate the landscape with their diverse range of products and solutions.
  • Based on technology, the PCR segment accounted for the largest share of the global DNA methylation detection technology market in FY2022.
  • Moreover, PCR is expected to maintain its dominance in the global DNA methylation detection technology market by technology due to its widespread adoption, versatility, and reliability.
  • Based on application, diagnostic research accounted for the largest share of the global DNA methylation detection technology market in FY2022, primarily due to clinicians' increasing focus on utilizing DNA methylation analysis for clinical diagnostics.

73% CNS ORR! FDA Granted ODD to Utidelone Injectable (UTD1) from Biostar Pharma for the Treatment of Breast Cancer Brain Metastasis

Retrieved on: 
Friday, March 29, 2024
ODD, Lung cancer, HER2, Epothilone, Survival, Prognosis, Brain, BBB, Central nervous system, Synthetic biology, Patient, SAN, CNS, Etoposide, Triple-negative breast cancer, Glioma, Traffic barrier, CBR, Bevacizumab, Breast cancer, PFS, FDA, TNBC

As of now, there is only one drug approved for the treatment of BCBM globally, suggesting huge unmet medical needs [1].

Key Points: 
  • As of now, there is only one drug approved for the treatment of BCBM globally, suggesting huge unmet medical needs [1].
  • Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux.
  • The FDA granted ODD to utidelone injectable for the treatment of BCBM based on these promising data.
  • Considering utidelone's excellent BBB-crossing capability and its therapeutic potential for brain tumors, Biostar Pharma also plans to advance the clinical studies of utidelone injectable for the treatments of other brain tumors such as lung cancer brain metastasis and glioma this year.

EveryLife Foundation for Rare Diseases Welcomes Michael Pearlmutter as CEO

Retrieved on: 
Thursday, March 28, 2024
Diagnosis, CPRN, Cerebral palsy, Disease, Science, Caregiver, Partnership, Empathy, Executive, Patient, Public, AI, Clinical trial, Prognosis, Optimism

WASHINGTON, March 28, 2024 /PRNewswire/ -- Building on the legacy of 15 years as a growing and impactful foundation serving the rare disease community, the EveryLife Foundation for Rare Diseases announces the appointment of Michael Pearlmutter into the new role of Chief Executive Officer of the foundation.

Key Points: 
  • WASHINGTON, March 28, 2024 /PRNewswire/ -- Building on the legacy of 15 years as a growing and impactful foundation serving the rare disease community, the EveryLife Foundation for Rare Diseases announces the appointment of Michael Pearlmutter into the new role of Chief Executive Officer of the foundation.
  • Michael also has firsthand experience with a rare disease, furthering his dedication and personal connection to the mission of the EveryLife Foundation.
  • Vicki Seyfert-Margolis, Chair of the Board of Directors at the EveryLife Foundation for Rare Diseases, expressed excitement about Pearlmutter's appointment, stating, "Michael's dynamic leadership and personal connection to the rare disease community make him the ideal choice to lead our Foundation.
  • Upon his appointment, Pearlmutter shared his enthusiasm, "I am excited to be stepping into the role of CEO at the EveryLife Foundation for Rare Diseases.

Caris Life Sciences to Showcase Research Highlighting the Clinical Value of Comprehensive Molecular Profiling at the American Association for Cancer Research Annual Meeting

Retrieved on: 
Thursday, March 28, 2024
Abstract, NCI, FOLFIRI, Prostate cancer, Immunotherapy, Adenocarcinoma, Colorectal cancer, PDLIM2, Physician, Patient, Lung, Biomarker, MSI, Breast, Cancer, AI, Doctor of Philosophy, Special session, MD, Lung cancer, Medicine, MBA, FOLFOX, AACR, PIM, MSS, Booth, POA, MRD, Future, Prognosis, SSP, ANTXR1, Vaccine

IRVING, Texas, March 28, 2024 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, today announced that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present 10 studies across eight tumor types at the 2024 American Association for Cancer Research (AACR) Annual Meeting on April 5-10, 2024, in San Diego, CA, at Booth Number 1105. Caris President, David Spetzler, MS, PhD, MBA, will lead an AACR Scientist ↔ Survivor Program® Special Session titled, "Very Early Cancer Detection Assays: The Future or Fantasy," on Tuesday, April 9, from 1:00 – 1:45 PM.

Key Points: 
  • Tissue-specific thresholds and microenvironment correlates of tumor mutation burden associated with immunotherapy benefit and prognosis in microsatellite stable cancers.
  • (Poster Number: 7037/4)
    Poster and abstract summaries highlighting the Caris research presented at AACR 2024 will be available onsite at Caris' Booth (# 1105).
  • The POA includes 91 cancer centers, academic institutions, research consortia and healthcare systems, including 43 NCI-designated cancer centers, collaborating to advance precision oncology and biomarker-driven research.
  • POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients.

Navigating Lung Cancer: 5 Essential Facts Families Should Know About Lung Nodules and Staging

Retrieved on: 
Wednesday, March 27, 2024
Diagnosis, Lung cancer, Metastasis, X-ray, Patient, Research, Cancer, Hope, Lymph, American Lung Association, Prognosis, Physician, Family, Primary tumor, Medical imaging

CHICAGO, March 27, 2024 /PRNewswire/ -- About every two and a half minutes, someone in the U.S. is diagnosed with lung cancer. The diagnosis process usually starts with a suspected "nodule." The process of "suspected nodule" to treatment (or other next steps) can be confusing to a person impacted and their family. To help empower people who are newly diagnosed with lung cancer with critical knowledge about lung nodules, staging and treatment, the American Lung Association and Olympus partnered to launch a new educational campaign.

Key Points: 
  • To help empower people who are newly diagnosed with lung cancer with critical knowledge about lung nodules, staging and treatment, the American Lung Association and Olympus partnered to launch a new educational campaign .
  • While it may seem like a simple step in the diagnostic process, staging lung cancer can be complicated.
  • Here are five things that people should know about lung cancer staging:
    There are 3 main scenarios in which lung nodules are found: Lung nodules show up on imaging tests like X-rays and CT scans.
  • The Lung Association has new resources about staging and lung nodules: Through this campaign, resources are available to provide more information about lung nodules and staging at Lung.org/lung-nodules .

Heart Failure Prevention: Early Detection Matters, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, March 26, 2024
Innovation, Medicine, Doctor of Pharmacy, Patient, Artificial intelligence, Death, MD, MBA, Heart failure, Prognosis, Cone Health, Cardiovascular disease, Physician, Health

TORONTO, March 26, 2024 /PRNewswire-PRWeb/ -- In the United States, the healthcare industry is reactive, focused on treating diseases that have already manifested and are driving individuals to seek care. But what if we turned this reactive approach into one that is proactive, focused on catching diseases earlier when the patient's prognosis is exponentially better? Structural and functional heart disease, as seen in heart failure, is a prime example of how early disease detection can greatly improve patient outcomes.

Key Points: 
  • In this free webinar, gain a better understanding of the stages of heart failure and why early detection is essential for improving patient outcomes.
  • Attendees will learn about the current guidelines for the detection and management of heart disease.
  • Structural and functional heart disease, as seen in heart failure, is a prime example of how early disease detection can greatly improve patient outcomes.
  • Register for this webinar today to learn about advances in healthcare delivery for heart failure prevention.